In the present study, Epstein-Barr virus (EBV) isolates from l 8 malignant tumors (angioimmunoblastic lymphadenopathy [AILD], n = 4; Hodgkin's disease [HDI, n = 3; pleomorphic T-cell non-Hodgkin's lymphoma [l-NHLI, n = 1; &cell nonHodgkin's lymphoma [B-NHL], n = 8; gastric carcinoma, n = 2) as well as from 10 tonsils of EBV-seropositive children and from peripheral blood mononuclear cells of 12 children with uncomplicated infectious mononucleosis (IM) and of a boy with severe chronic active EBV infection ware genotyped in the EBV nuclear antigen-2 (EBNA-2) gene. A total of 40 of 41 isolates harbored EBV type 1; in 1 specimen (tonsil), only EBV type 2 was found. Further molecular characterization of EBV t y p e -l wild-type isolates in the EBNA-2 gene and in the 40-kb distant EBV-encoded small RNAs (EBER) region showed that different groups of stable EBV t y p e -l variant strains exist in vivo both in benign and malignant lymphatic tissue. Group 1 is composed of EBV type-l isolates (B-NHL, n = 3; T-NHL, n = 1; HD, n = 1; IM, n = 4) that showed a 695-8-Iike DNA sequence pattern in both PSTEIN-BARR VIRUS (EBV), the causative agent of infectious mononucleosis (M), has been associated with endemic Burkitt's lymphoma (BL), with nasopharyngeal carcinoma, with certain B-and T-cell lymphomas, with approximately 50% of Hodgkin's disease (m), with different types of gastric carcinomas, and with B-cell lymphoproliferative disorders in immunosuppressed individuals."' According to their DNA sequence (and protein) divergence within the EBV nuclear antigens (EBNA-2, -3a, -3b, -3c) and the 40-kb distant EBV-encoded small RNAs (EBER) region, two types of EBV (EBV type 1, EBV type 2) have been identified."" EBNA-2 is of particular interest because this protein plays an essential role in the transformation process of B lymphocytes by EBV"*" and seems to be a critical determinant for EBV-induced lymphoma tumor growth in immunodeficient severe combined immunodeficiency disease mice.I3 The biological differences between EBV type 1 and EBV type 2 appear to be mainly caused by the divergence within the EBNA-2 protein, because EBV type 2, when compared with EBV type 1, has a lower transforming efficiency, a poorer initial outgrowth, and a higher cell-density dependence for cell viability in ~i t r 0 . l~ Both EBV types occur worldwide, with different geographical distributions. In general, EBV type 1 is the predominant type in lymphatic cells of EBV-infected individuals. Immunodeficient hosts, especially those with acquired immunodeficiency syndrome, show increased infection rates with EBV type 2.15 However, little is known of whether both strains really differ in their biological activities in vivo. Recently, Aitken et a l l 6 found EBNA-2 sequence heterogeneity in EBV type-l isolates from four African and New Guinea endemic BL cases, suggesting that variant EBV type-l substrains may be associated with these tumors. Different point mutations in the EBNA-2 gene have been described in some EBV type-l isolates from human immunodeficiency virus-infected patients but not from human immunodeficiency virus-negative subjects."
According to their DNA sequence (and protein) divergence within the EBV nuclear antigens (EBNA-2, -3a, -3b, -3c) and the 40-kb distant EBV-encoded small RNAs (EBER) region, two types of EBV (EBV type 1, EBV type 2) have been identified."" EBNA-2 is of particular interest because this protein plays an essential role in the transformation process of B lymphocytes by EBV"*" and seems to be a critical determinant for EBV-induced lymphoma tumor growth in immunodeficient severe combined immunodeficiency disease mice.I3 The biological differences between EBV type 1 and EBV type 2 appear to be mainly caused by the divergence within the EBNA-2 protein, because EBV type 2, when compared with EBV type 1, has a lower transforming efficiency, a poorer initial outgrowth, and a higher cell-density dependence for cell viability in ~i t r 0 . l~ Both EBV types occur worldwide, with different geographical distributions. In general, EBV type 1 is the predominant type in lymphatic cells of EBV-infected individuals. Immunodeficient hosts, especially those with acquired immunodeficiency syndrome, show increased infection rates with EBV type 2.15 However, little is known of whether both strains really differ in their biological activities in vivo. Recently, Aitken et a l l 6 found EBNA-2 sequence heterogeneity in EBV type-l isolates from four African and New Guinea endemic BL cases, suggesting that variant EBV type-l substrains may be associated with these tumors. Different point mutations in the EBNA-2 gene have been described in some EBV type-l isolates from human immunodeficiency virus-infected patients but not from human immunodeficiency virus-negative subjects."
The present study was undertaken to evaluate if stable and constant nucleotide changes in the EBNA-2 gene are viral genes. Group 2 isolates (HD, n = 1 ; AILD, n = 1; B-NHL, n = 1; tonsils of EBV-seropositive children, n = 9; IM, n = 2) showed a nucleotide change at position 49095 in the EBNA-2 gene, leading t o an amino acid substitution (Pro -, Ser), and EBV type9 sequences in the EBER region. EBV type-l isolates that fall into group 3 (AILD, n = 3; HD, n = 1; B-NHL, n = 4; gastric carcinoma, n = 2; IM, n = 6; severe chronic active EBV infection, n = 1) were characterized by typical nucleotide changes and a 3-bp insertion (CTC; extra Leu residue) in the EBNA-2 gene and an EBV type-2-specific sequence pattern in the EBER region. These EBV type-l variant strains may represent the most prevalent circulating EBV type-l strains in the exposed population and seem not to be restricted to a certain EBV-associated disease or tumor type. However, analysis of more EBV isolates from benign and malignant lesions must show whether more EBV type-1 substrains exist in vivo. 0 1996 b y The American Society of Hematology.
a common phenomenon of EBV type-l wild-type isolates derived from patients with different malignant lymphomas and from children with benign clinical conditions. We extended this analysis to another locus, the 40-kb distant EBER region, using single-strand conformation polymorphism (SSCP). Cell lines. The B95-8 line was used as a source of EBV type-1 prototype." This EBV strain was originally established from an 1580 IM patient." The BL cell line Jijoye was used as a source of EBV type-:! prototype."
MATERIALS AND METHODS

Clinical
Polymerase chain reaction (PCR) of o portion of the EBNA-2 gene. Total DNA was extracted from biopsy material, PBMCs, or cell lines and was then amplified in duplicates either with EBNA-2 primers specific for EBV type 1 (S'-TCTTGATAGGGATCCGCTA-GGATA-3'. nucleotide positions 48839-48862: and S'-ACCGTGG-TTCTGGACTATCTGGATC-3'. nucleotide positions 49335-4931 I ) or with EBNA-2 primers specific for EBV type 2 (S'-ACTGGATAT-GAATCCCCTGGGCAG-3'. nucleotide positions 48766-48789; and S'-GAGTCCTGTACTATCAGAACTACAATG-3', nucleotide positions 49231-4920S).'".'2 The amplified products had a size of 497 bp (EBV type-l sequences) or 466 bp (EBV type-2 sequences), respectively. PCR conditions have been reported eisewhere."
Southern blot h,vbridi:atior~ ona/ysi.r. To control the specificity of EBNA-2 genotyping, PCR products were electrophoresed in a 2% agarose gel and were Southem-blotted onto a nylon support (Gene Screen Plus; DuPont, Braunschweig, Germany). Membranes were then hybridized with an internal "P-labeled EBNA-2 DNA probe that was either specfic for EBV type I or specific for EBV type 2. The internal probe specific for EBV type 1 (155 bp) was generated by PCR using the primers S'-CAACCACTCATGATGC-CACCAAGGC-3' (nucleotide positions 49077-49101) and S'-GAT-GGTGTGGGTTGAAGTTCGGTAG-3' (nucleotide positions 4923 1-49207) and as template EBV type-l prototype strain B95-8.
The internal probe specific for EBV type 2 (IS5 bp) was generated by PCR using the primers S'4TGCCCATGGTAGCClTAGGA-
CATA-3'(nucleotide positions 49004-49028) and S'-AGACTTAG-TTGATGCCCTAGTGTGA-3' (nucleotide positions 49158-49134)
and as template EBV type-2 prototype strain Jijoye. Hybridization probes were radiolabeled by inclusion of 2 pCi [a-"P]-deoxycytidine triphosphate (3.000 Cilmmol) in the PCR. PCR conditions were the same as indicated above." After washing under stringent conditions blots were dried and subjected to autoradiography at -70°C with intensifying screens.
Direct DNA seqrcencirtg uf EBNA-2 PCR products. Doublestranded PCR products were purified with PrimeErase Quick Push Columns (Stratagene, Heidelberg, Germany) and were directly cycle-sequenced by the dideoxy-termination method using "S-deoxyadenosine triphosphate and the Exo(-)Pfu Cyclist DNA Sequencing Kit (Stratagene) according to the manufacturer's protocol. Samples were electrophoresed on 6% polyacrylamide/8.3 mol/L urea sequencing gels (Roth, Karlsruhe, Germany), dried, and exposed to Kodak XAR-S films (Eastman-Kodak, Rochester. NY).
SSCP analysis .f the EBER region. For genotyping of EBV isolates in the EBER gene, which reveals 6 type-specific point mutations: we used SSCP analysis similar to that described e l s e~h e r e .~" .~~ The genotype-specific point mutations can easily be detected by characteristic shifts in mobility because of conformational changes of the (single-stranded) DNA sequences.
PCR fragments with a size of 190 bp were amplified from 200 ng of genomic DNA in a S0 pL mixture containing I pmol/L of both EBER-specific primers S'-GTGGTCCGCATGTTTTGATC-3'
(nucleotide positions 6780 -6799) and S'-GCAACGGCTGTCCTG-TTTGA-3' (nucleotide positions 6969 -6950),'1200 prnol/L of each deoxynucleotide triphosphate, 0. I S pL "P-labeled deoxycytidine triphosphate (3.000 Cilmmol; Amersham Buchler, Braunschweig, Germany), 10 mmol/L Tris-HCI (pH 8.3). S0 mmol/L KCI, I .S mmol/L MgCI?, and 2.5 U of Taq DNA polymerase (Boehringer, Mannheim, Germany). Initial denaturation was for S minutes at 94°C. Subsequently, 35 cycles with denaturation for 30 seconds at 94°C. annealing for 30 seconds at 57°C. and extension for I minute at 72°C were performed in a Perkin Elmer-Cetus thermocycler (Perkin ElmerCetus, Nonvalk. CT). A total of S pL of the final product was mixed and diluted with 45 pL formamide-loading buffer (95% formamide, 10 mmol/L EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol) and was heat-denatured for 10 minutes at 80°C. A total of 4 pL of the mixture was electrophoresed in a nondenaturing 5% polyacrylamide gel (Roth) containing S% glycerol in 0.SX Trisborate-EDTA (TBE) buffer at room temperature for 7 hours at 10 W. The gel was dried and exposed to Kodak XAR-S films.
RESULTS
DNA was isolated from biopsy specimens of 18 malignant tumors (AILD, B-and T-NHL, HD, and gastric carcinoma), from 10 tonsils (of EBV-seropositive children who were tonsillectomized for recurrent chronic tonsillitis), from PBMCs of 12 children with uncomplicated acute IM, and from PBMCs of a boy with SCAEBV and were examined
For for the presence of EBV. All but 1 of the biopsy samples contained EBV type-1 genomes as determined by FCR using genotype-specific EBNA-2 primers (Figs l a and b) . Only 1 isolate from benign tonsil tissue contained EBV type 2. Double infections with both strains, EBV type 1 and EBV type 2, were not detected in any of the pathological specimens. To detect DNA sequence variations within the EBNA-2 gene that may possibly allow the definition of EBV type-l variant strains, EBNA-2 PCR products of all isolates were directly sequenced and compared with known EBNA-2 sequences of EBV type-l prototype strain B95-8 and EBV type-2 prototype strains AG876 and Jijoye (Table 1) . In addition, all isolates were simultaneously genotyped in a gene 40-kb distant, the EBER region. As shown in Table 1 , the isolates could be classified into three different groups according to their individual EBNA-2 sequence pattern and their EBER genotype.
Pro
Isolates showing a B95-&like pattern at both gene loci fall into group 1 (Fig 2% right EBV type-l substrains of group 2 were characterized by a nucleotide mismatch in the EBNA-2 gene at position 49095 (C -+ T) leading to an amino acid exchange (Pro + Ser) and EBV type-2 sequences in the EBER region. Figure 2a (middle) shows the EBNA-2 sequence pattern of a group-2 isolate (AILD-2). In the EBER region, this isolate was found to contain EBV type-2 sequences (Fig 3, lane 10) .
Interestingly, in 2 brothers with X-linked lymphoproliferative disease who developed histologically different malig- Fig 3. PCR-SSCP analysis of EBER region. PCR products of 190 bp were amplified using EBER-specific primers, were denatured, and were subjected t o SSCP analysis in a nondenaturing 5% polyacrylamide gel, as described in the Materials and Methods. Genotype-specific point mutations were visualized as shifts in mobility. The single-stranded DNA resolved into the three upper bands, which is caused by the faster mobility of the sense strand when compared with that of the antisense strand." The reason for the third (fainter) upper band remains unclear. Probably, it contains a partially denatured complex of senselantisense strands. The thick band with the fastest mobility represents the doublestranded DNA (dsDNA). Lane 1, 895-8 (EBV type-l prototype strain); lane 2, Jijoye (EBV type9 prototype strain); nant tumors, namely HD (HD-2) and small-cell lymphocytic B-NHL with plasmacytoid features (B-NHL-4), the same EBV type-l substrain (group 2) was found in tumor biopsy specimens. This might suggest that the strain was transmitted from one family member to another.
Somewhat surprisingly, all 9 EBV type-l isolates from tonsils of children with chronic tonsillitis examined so far could be classified as group 2 EBV type-l substrains.
Group 3 is composed of EBV isolates with EBNA-2 nucleotide mismatches at positions 49057 (A + G ) , 49091 (G + T), 491 13 (A + T) and 49170 (C T), leading to three amino acid substitutions (Gln + Arg, Met + Ile, Thr + Ser) and an insertion of three nucleotides (CTC) between position 49 l36 and 49 137 resulting in an extra amino acid (Leu) (Figs 2a and b and Table 1 ). All these isolates contained EBV type-2 sequences in the EBER region (Fig  3) . In 9 isolates (AILD-I; AILD-3; B-NHLJ; B-NHL-6; SCAEBV; IM, n = 4) an additional nucleotide mismatch Table l) .
Recently, a region of the EBNA-2 gene of the African endemic BLs W91 ," FWA and ODH'" has been sequenced and compared with the corresponding region of EBV type-1 strain B95-8. According to the characteristic nucleotide mismatches in EBNA-2, these three strains most probably belong to the category of group 3 substrains (Table l) . However, genotyping in the EBER region has been not performed in any of these isolates.
DISCUSSION
Our results show that distinct stable EBV type-l variant strains are common in vivo. According to their characteristic sequence pattern in the EBNA-2 and the EBER genes, we can define three groups of EBV type-l substrains. Group 1 is composed of EBV isolates with a B95-8-like pattern at the EBNA-2 and the EBER gene locus. Group 2 isolates are characterized by one nucleotide mismatch (C + T) in the EBNA-2 gene at position 49095 and by EBV type-2-like sequences in the EBER region. Group 3 isolates show a W91-like pattern in the EBNA-2 gene and EBV type-2-like sequences in the EBER region.
These EBV type-l variant strains seem not to be restricted to a certain clinical disorder or tumor type. We could also show that the same EBV type-l substrain (of group 2) occurred in histologically different malignant tumors of 2 brothers who both carried the defective gene of X-linked lymphoproliferative disease,"' suggesting intrafamilial transmission of this EBV substrain. During IM, the infection is not only restricted to B cells, which morphologically include Reed-Stemberg-like cells, immunoblasts, medium-sized lymphoid cells, and plasma cells. In addition, varying numbers of T lymphocytes are also infected by EBV.' "' ' Therefore, it is tempting to assume that these EBV-infected B-and T-cell populations in IM might represent the benign counterparts of EBV-infected tumor cells in BL, HD, and different B-and T-cell lymphomas. Our findings that the EBV type-l variant strains found in benign clinical conditions (such as 1M) matched the EBV type-l variant strains isolated from different malignant tumors might support this suggestion. In addition, EBV variant strains with certain deletions/mutations within the gene of EBV latent membrane protein-l have been found in both malignant and benign EBV-associated diseases." These findings and our findings might suggest that these EBV variant strains may represent the most prevalent circulating EBV For personal use only. on October 27, 2017. by guest www.bloodjournal.org From strains to which the patient population is exposed. However, analysis of more EBV isolates from benign and malignant lesions must show whether more EBV type-l substrains exist in vivo.
The biological consequences of EBV variant strains in vivo are still not clear. Because the W91 strain has a "normal" transforming capacity in vitro"." and in vivo," we suggest that other EBV isolates from group 3 also do not significantly differ in their biological behavior when compared with B95-8-like group-l EBV type-l strains.
Intact and deleted W91 strain-like EBNA-2 sequences have been recently identified in two patients with oral hairy leukoplakia,** suggesting that group-3 (and most probably also group-2) EBV type-l variant strains may also persist within the epithelial compartment.
It has been suggested that the sequences of the EBNA-2 and EBER genes normally belong to the same genotype.' However, all isolates investigated in this study and classified as belonging to group 2 and 3 of EBV type-l variant strains carried EBV type-l sequences in the EBNA-2 gene while maintaining EBV type-2 sequences in the EBER region. Similar "discrepant" results of genotyping at both loci, EBNA-2 and EBER, have been recently described in some BL and nasopharyngeal carcinoma cell lines and in a higher percentage of HD biopsy and posttransplantation lymphoproliferative lesions.29 It is conceivable that these "mixed" isolates, when sequenced in the EBNA-2 gene, may also represent EBV type-1 variant strains of either group 2 or group 3. It is very likely that all these mixed EBV variant strains with type-l sequences in the EBNA-2 gene show the biological behavior of the EBV type-l prototype strain B95-8.
The pathogenesis of EBV-associated diseases is complex, involving viral, immunologic, and genetic factors. To what extent certain EBV type-l variant strains may influence the course of EBV infection is not known at present. Functional assays are needed to test and compare the biological consequences of EBV type-l variant strains.
